About: Biologically targeted cancer therapy and marginal benefits: are we making too much of too little or are we achieving too little by giving too much?

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Biologically targeted cancer therapy and marginal benefits: are we making too much of too little or are we achieving too little by giving too much? Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

scientific article published on December 2010

Attributes	Values
rdf:type	Item
description	videnskabelig artikel (da) article científic (ca) articolo scientifico (it) artigo científico (pt) bilimsel makale (tr) vedecký článok (sk) vetenskaplig artikel (sv) vědecký článek (cs) wetenschappelijk artikel (nl) wissenschaftlicher Artikel (de) научни чланак (sr) article scientifique (fr) artículu científicu espublizáu en 2010 (ast) наукова стаття, опублікована в грудні 2010 (uk) مقالة علمية نشرت في ديسمبر 2010 (ar) scientific article published on December 2010 (en)
publication date	wds:Q37822201-4461C7B3-AFE2-424B-9E2C-E154437BA619
publication date	2010-12-01 00:00:00Z (xsd:dateTime)
language of work or name	wds:Q37822201-E941A373-43D0-4F27-BE0B-1719802A87BE
language of work or name	English
cites work	wds:Q37822201-87B6D140-1E4B-4906-88AD-8B13F9FB68DB wds:Q37822201-A702D4C9-0586-436C-9C71-D4747668F7FC wds:Q37822201-CBB44C9F-50A8-4D94-B70A-EA9217201033
cites work	The genomic landscapes of human breast and colorectal cancers The consensus coding sequences of human breast and colorectal cancers Core signaling pathways in human pancreatic cancers revealed by global genomic analyses
author name string	wds:Q37822201-2F3594CC-0481-4BE4-8738-DC4F70B0C986
author name string	David R Parkinson
rdfs:label	Biologically targeted cancer therapy and marginal benefits: are we making too much of too little or are we achieving too little by giving too much? (en) Biologically targeted cancer therapy and marginal benefits: are we making too much of too little or are we achieving too little by giving too much? (nl) Biologically targeted cancer therapy and marginal benefits: are we making too much of too little or are we achieving too little by giving too much? (ast)
skos:prefLabel	Biologically targeted cancer therapy and marginal benefits: are we making too much of too little or are we achieving too little by giving too much? (en) Biologically targeted cancer therapy and marginal benefits: are we making too much of too little or are we achieving too little by giving too much? (nl) Biologically targeted cancer therapy and marginal benefits: are we making too much of too little or are we achieving too little by giving too much? (ast)
name	Biologically targeted cancer therapy and marginal benefits: are we making too much of too little or are we achieving too little by giving too much? (en) Biologically targeted cancer therapy and marginal benefits: are we making too much of too little or are we achieving too little by giving too much? (nl) Biologically targeted cancer therapy and marginal benefits: are we making too much of too little or are we achieving too little by giving too much? (ast)
author	wds:Q37822201-C952A3D0-6C69-4AA8-B28C-0CFEFD445872
author	Tito Fojo
title	wds:Q37822201-CC996FEF-C484-47A8-8AEE-F0693F9210E6
title	Biologically targeted cancer therapy and marginal benefits: are we making too much of too little or are we achieving too little by giving too much? (en)
page(s)	wds:Q37822201-714FF996-A911-4320-9E60-2C4B7EE91259
page(s)	5972-5980
instance of	wds:Q37822201-D998D6AF-9BCF-4900-8A92-8B68881DE70D wds:Q37822201-bce6c3d8-c307-4570-b2fe-c74ebf211926
instance of	review article scholarly article
PubMed ID	wds:Q37822201-729C5F40-1D8A-44DD-881F-ABAC8BF682BF
PubMed ID	http://rdf.ncbi.nlm.nih.gov/pubchem/reference/21169250
PubMed ID	21169250
published in	wds:Q37822201-838ED733-44B6-4E06-B980-8194982CCFBC
published in	Clinical Cancer Research
issue	wds:Q37822201-37E7408A-FF94-48D4-BB38-5911F454EC4B
volume	wds:Q37822201-5F749955-6F13-4467-9EED-331747D243E8
issue	24
volume	16
DOI	wds:Q37822201-86986811-2672-4A05-9A51-5C37DEB7B29E
DOI	http://dx.doi.org/10.1158/1078-0432.CCR-10-1277
DOI	10.1158/1078-0432.CCR-10-1277
is about of	https://www.wikidata.org/wiki/Special:EntityData/Q37822201
is cites work of	Exploiting the curative potential of adoptive T-cell therapy for cancer Tumor markers in clinical practice: a review focusing on common solid cancers Functional profiling of live melanoma samples using a novel automated platform Translating cancer 'omics' to improved outcomes Antiangiogenic therapy for cancer: an update The growing complexity of HIF-1α's role in tumorigenesis: DNA repair and beyond. Primary extraosseous Ewing sarcoma of the lung in children The value of progression-free survival to patients with advanced-stage cancer Targeting angiogenesis in lung cancer - Pitfalls in drug development From modules to medicine: How modular domains and their associated networks can enable personalized medicine Towards engineering hormone-binding globulins as drug delivery agents The return of metabolism: biochemistry and physiology of the pentose phosphate pathway Kinase inhibitors and monoclonal antibodies in oncology: clinical implications Delivering affordable cancer care in high-income countries Personalized cancer medicine--advances and socio-economic challenges Cancer cell signaling pathways targeted by spice-derived nutraceuticals CXCL12 (SDF1alpha)-CXCR4/CXCR7 pathway inhibition: an emerging sensitizer for anticancer therapies? Cancer as a metabolic disease: implications for novel therapeutics The Efficacy of Trastuzumab in Animal Models of Breast Cancer: A Systematic Review and Meta-Analysis Dose selection trial of metronomic oral vinorelbine monotherapy in patients with metastatic cancer: a hellenic cooperative oncology group clinical translational study Cost estimates and economic implications of expanded RAS testing in metastatic colorectal cancer Progress against cancer (1971-2011): how far have we come? NANOMEDICINE: will it offer possibilities to overcome multiple drug resistance in cancer? Coordinated targeting of the EGFR signaling axis by microRNA-27a*. Prediction of recurrence-free survival using a protein expression-based risk classifier for head and neck cancer The clinical viewpoint: definitions, limitations of RECIST, practical considerations of measurement Antiangiogenic therapy for advanced renal cell carcinoma: management of treatment-related toxicities Just caring: assessing the ethical and economic costs of personalized medicine. "Just caring": can we afford the ethical and economic costs of circumventing cancer drug resistance? Drugs, cancer and end-of-life care: a case study of pharmaceuticalization? The Repurposing Drugs in Oncology (ReDO) Project. The unpluggable in pursuit of the undruggable: tackling the dark matter of the cancer therapeutics universe Cancer Prevention and Therapy: Integrating Traditional Korean Medicine Into Modern Cancer Care 6-shogaol induces apoptosis and enhances radiosensitivity in head and neck squamous cell carcinoma cell lines. Effect of Metformin and Statin Use on Survival in Pancreatic Cancer Patients: a Systematic Literature Review and Meta-analysis Repurposing existing medications as cancer therapy: design and feasibility of a randomized pilot investigating propranolol administration in patients receiving hematopoietic cell transplantation. Cancer drug development: The missing links New tools for old drugs: Functional genetic screens to optimize current chemotherapy. Kinetic modelling of quantitative proteome data predicts metabolic reprogramming of liver cancer

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 172 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software